1 hr ago

Jefferies Favors Hospital Stocks Despite Cancer Drug Price Cap Concerns

Jefferies Favors Hospital Stocks Despite Cancer Drug Price Cap Concerns
Cancer drug price caps: Why Jefferies picks Fortis, Apollo, Manipal despite SC scrutiny · financialexpress.com

The government is considering limits on how much hospitals and sellers can mark up some cancer medicines.

The Supreme Court is due to hear petitions about high medicine mark-ups on October 12.

Jefferies says new limits could put some pressure on hospital earnings at first.

It thinks hospitals may be able to respond by managing costs or adjusting procedure prices.

The brokerage says earlier price cuts on some medical products were followed by changes that helped hospitals recover their margins.

It also says hospital shares are cheaper than they were a year ago.

Jefferies expects demand for quality hospital care to support the sector.

It prefers Fortis Healthcare, Manipal Hospitals and Apollo Hospitals among the listed hospital companies it follows.

The article also notes that rules on medical devices and consumables could change in the future.

Key facts

Proposed margin cap
30% of MRP for non-scheduled cancer medicines, according to media reports cited by Jefferies.
Earlier Jefferies scenario
A 16% margin cap on cancer drugs and a 5% cap on consumables.
Estimated earnings effect
Jefferies estimated a 2–5% EBITDA reduction under its earlier scenario.
Consumables share
Jefferies says consumables account for around 12–15% of a patient's hospital bill.
Hospital stock valuations
The article says stocks traded at around 21–25 times estimated FY28 EV/EBITDA, compared with 25–35 times a year earlier.
Jefferies' preferred order
Fortis Healthcare, Manipal Hospitals, Apollo Hospitals, Max Healthcare Institute and Medanta.
Next court hearing
October 12.

Sources

Related news